Status:

RECRUITING

IUL Study A Randomized Sham - Controlled Clinical Study

Lead Sponsor:

Medical University of Graz

Conditions:

Stress Urinary Incontinence

Eligibility:

FEMALE

18-80 years

Phase:

NA

Brief Summary

Primary aim of the study is to compare the impact of SUI on the VAS (visual analogue scale) 3 months after laser therapy versus sham laser therapy.

Detailed Description

Background: Stress urinary incontinence (SUI) has a huge impact on the quality of life (QoL) in women and its treatment is challenging. Intraurethral laser may be an additional treatment option. Stud...

Eligibility Criteria

Inclusion

  • Female between 18 and 80 years
  • Confirmed SUI through cough stress test within the last 24 months
  • SUI I-II° for more than 6 months
  • At least one incontinence episode per 24 hour period measured over three days according to a bladder diary
  • Valsalva leak-point pressure (VLPP) ≤60 cm H2O
  • Maximum cystometric capacity ≥250 mL
  • No pelvic surgery within last 6 months (including prolapse repair, subjects who have residual or recurrent SUI following colposuspension or a sling procedure may be included in the study if the procedure was conducted at least 6 months prior to screening /baseline visit)
  • BMI (body mass index) ≤35 kg/m2
  • Willing to give informed consent and complete the follow up schedule

Exclusion

  • Active lower urinary tract infections (urethritis, cystitis or vaginitis)
  • Three (3) or more cultured-proven bacterial urinary tract infection (UTI) in the last 12 months
  • Detrusor overactivity on urodynamics
  • Postvoiding residual (PVR) \> 100 ml
  • Previous urethral surgery (i.e. fistula or diverticula)
  • Pelvic organ prolapse grade \> 3 as defined by POP-Q and symptomatic
  • Known polyuria (\>3l/24h)
  • Unevaluated macro hematuria
  • Neurogenic bladder
  • Evidence of dysplasia in a Pap smear (done in the last 24 months)
  • Tumours of the Urinary tract
  • Previous radiation or brachytherapy to treat pelvic cancer
  • Uncontrolled diabetes
  • Active herpes genitalis
  • Pregnancy
  • Vaginal delivery within 6 months prior to the Screening/Baseline Visit

Key Trial Info

Start Date :

January 8 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04707690

Start Date

January 8 2021

End Date

January 1 2025

Last Update

January 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Departement of Obstetrics and Gynecology

Graz, Styria, Austria, 8036